SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    De Vivo DC, Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5(2):13441.
  • 2
    Pons R, De Vivo DC. Primary and secondary camitine deficiency syndromes. J Child Neurol 1995;10(suppl):2S824.
  • 3
    Pons R, Carrozzo R, Tein I, et al. Deficient muscle camitine transport in primary carnitine deficiency. Pediatr Res 1997;42:5837.
  • 4
    Garcia-Alvarez M, Nordli DR, De Vivo DC. Inherited metabolic disorders. In: EngelJJr, PedleyTA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott Raven, 1997:254762.
  • 5
    Morita J, Yuge K, Yoshino M. Hypocarnitinemia in handicapped individuals who receive a polypharmacy of antiepileptic drugs. Neuropediatrics 1986;17:2035.
  • 6
    Laub MC, Paetzke-Brunner I, Jaeger G. Serum camitine during valproic acid therapy. Epilepsia 1986;27:55962.
  • 7
    Melegh B, Kemer J, Kispál G, Acsádi G, Dani M. Effect of chronic valproic acid treatment on plasma and urinary camitine levels in children: decreased urinary excretion. Acta Paediatr Hung 1987; 28:13742.
  • 8
    Rodriguez-Segade S, Alonso de la Peña C, Tutor JC, et al. Camitine deficiency associated with anticonvulsant therapy. Clin Chim Acta 1989; 181:17582.
  • 9
    Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W, and the Collaborative Group for the Study of Epilepsy. Valproate, camitine metabolism, and biochemical indicators of liver function. Epilepsia 1990;31:34652.
  • 10
    Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum camitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991; 119;799802.
  • 11
    Opala G, Winter S, Vance C, Vance H, Hutchison HT. Linn LS. The effect of valproic acid on plasma camitine levels. Am J Dis Child 1991;145:9991001.
  • 12
    Winter SC, Szabo-Aczel S, Curry CJR, Hutchinson HT, Hogue R, Shug A. Plasma camitine deficiency: clinical observations in 51 pediatric patients. Am J Dis Child 1987;141:6605.
  • 13
    Stumpf DA, Parker WD Jr, Angelini C. Carnitine deficiency, organic acidemias, and Reye's syndrome. Neurology 1985;35:10415.
  • 14
    Ohtani Y, Endo F, Matsuda I. Camitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982; 101:7825.
  • 15
    Matsuda I, Ohtani Y. Camitine status in Reye and Reye-like syndromes. Pediatr Neurol 1986;2:904.
  • 16
    Coulter DL. Camitine deficiency: a possible mechanism for Val. proate hepatotoxicity [Letter]: Lancet 1984;1:689.
  • 17
    Coulter DL. Camitine, valproate, and toxicity. J Child Neurol 1991;6:714.
  • 18
    Bohles H, Richter K, Wagner-Thiessen E, Schafer H. Decreased serum carnitine in valproate induced Reye syndrome. Eur J Pediatr 1982;139:1856.
  • 19
    Murphy JV, Marquardt KM, Shug AL. Valproic acid associated abnormalities of camitine metabolism. Lancet 1985;1:8201.
  • 20
    Bohan TP, Roe CR, Rogers P, Vance C, Linn L. Valproate and camitine [Abstract]. Ann Neurol 1991;30:491.
  • 21
    Igarashi N, Sato T, Kyouya S. Secondary carnitine deficiency in handicapped patients receiving valproic acid and or elemental diet. Acta Paediatr Jpn 1990;32:13945.
  • 22
    Murphy JV, Marquardt KM, Shug A. Plasma and urine camitine concentrations in patients receiving valproic acid [Abstract]. Paediatr Res 1984;18:380A.
  • 23
    Shapira Y, Gutman A. Muscle carnitine deficiency in patients using valproic acid. J Pediatr 1991;118:6469.
  • 24
    Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment. J Child Neurol 1995;10(suppl):2S329.
  • 25
    Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ. Valproylcamitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 1985; 145:6976.
  • 26
    Stanley CA, Berry GT, Treem WR. Differences in the evolution of camitine deficiency among secondary camitine deficiency disorders. In: Proceedings of the 5th International Congress on Inborn Errors of Metabolism. Asilomar , CA , June 1–5, 1990 (Abstract W17.10.).
  • 27
    Li J, Norwood DL, Mao L-F, Schulz H. Mitochondria1 metabolism of valproic acid. Biochemistry 1991;30:38894.
  • 28
    Tein I, Xie ZW. Reversal of VPA-induced impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 1994;204:7538.
  • 29
    Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:114352.
  • 30
    Haas R, Stumpf DA, Parks JK, Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981; 31:14736.
  • 31
    Becker C-M, Harris RA. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 1983; 223:38192.
  • 32
    Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HSA. The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 1983;32:188792.
  • 33
    Benavides J, Martin A, Ugarte M, Valdivieso F. Inhibition by valproic acid of pyruvate uptake by brain mitochondria. Biochem Pharmacol 1982;31:16334.
  • 34
    Rogiers V, Vandenberghe Y, Vercruysse A. Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes. Xenobiotica 1985; 15:75965.
  • 35
    Gerber N, Dickinson RG, Harland RC, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979;95:1424.
  • 36
    Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia 1993;34:17783.
  • 37
    Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. US. experience since 1986. Neurology 1996;46:4659.
  • 38
    Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987;28(suppl 2):S239.
  • 39
    Ater SB, Benefield WH, Saklad JJ, Saklad SR. A developmental center population treated with VPA and L-camitine. In: Update 1993: inborn errors of metabolism in the patient with epilepsy. Sigma-Tau Pharmaceuticals; 1993.
  • 40
    Coulter DL. Camitine, valproate and toxicity. J Child Neurol 1991; 6:714.
  • 41
    Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:37985.
  • 42
    Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities: II. U.S. experience since 1984. Neurology 1989; 39:2017.
  • 43
    Bohan TP, Helton E, McDonald II, et al. Efficacy of L-camitine treatment for valproate-induced hepatotoxicity. Submitted to New Engl J Med, 1997.
  • 44
    Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;337:11121.
  • 45
    Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979;2:1097100.
  • 46
    Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence Acta Paediatr 1995;334:935.
  • 47
    Camiñia MF, Rozas I, Gómez M, Paz JM, Alonso C, Rodriguez-Segade S. Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues. Br J Pharmacol 1991; 103:117983.
  • 48
    Prasad AN, Stafstrom CE, Holmes GL. Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Epilepsia 1996:37(suppl I):S8195.
  • 49
    Nordli DR Jr, De Vivo DC. The ketogenic diet revisited: back to the future. Epilepsia 1997;38:7439.
  • 50
    Wheless JW. The ketogenic diet: fa(c)t or fiction [Editorial]. J Child Neurol 1995;10:41923.
  • 51
    Appleton DB, De Vivo DC. An animal model for the ketogenic diet. Epilepsia 1974;15:2117.
  • 52
    Kinsman SL, Vining EPG, Quaskey SA, Mellits D, Freeman JM. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992:33:11326.
  • 53
    De Vivo DC, Leckie MP, Ferrendelli JS, McDougal DB. Chronic ketosis and cerebral metabolism. Ann Neurol 1978;3:3317.
  • 54
    Withrow CD. The ketogenic diet: mechanisms of anticonvulsant action. In: GlaserGH, PenryJK, WoodburyWM, eds. Antiepileptic drugs: mechanisms of action. New York Raven Press, 1980: 63542.
  • 55
    Hori A, Tandon P, Holmes GL, Stafstrom CE. Ketogenic diet: effects on expression of kindled seizures and behavior in adult rats. Epilepsia 1997;38:7508.
  • 56
    Nordli DR, Koenigsberger D, Carroll J, De Vivo DC. Successful treatment of infants with the ketogenic diet [Abstract]. Ann Neurol 1995;38:523.
  • 57
    Wexler ID, Hemalathu SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets: studies in patients with identical mutations. Neurology 1997;49L 165561.
  • 58
    Freeman JM, Vining EPG, Swink TD, Casey JC, Kelly MT. Effectiveness of the ketogenic diet in difficult to control seizures: 150 consecutive cases followed up more than 6 months [Abstract]. Epilepsia 1997;38(suppl 8):194.
  • 59
    Rutledge SL, Geraghry MT, Vining EPG, Thomas G. Hypocarnitemia and the ketogenic diet. Ann Neurol 1989;26:472.
  • 60
    Demeritte EL, Ventimiglia J, Coyne M, Nigro MA. Organic acid disorders and the ketogenic diet [Abstract]. Ann Neurol 1996;40:305.
  • 61
    Chez MG, Buchanon C, Kessler J, Demski P, Wagner E. Carnitine deficiency in patients starting the ketogenic diet [Abstract]. Neurology 1997;48:Al10.
  • 62
    Hunt PA, Pellock NM. Letter to the editor. Pediatrics 1995;96:1175.
  • 63
    Vance CK, Vance WH, Winter SC, Opala G, Szaho A, control of valproate-induced hepatotoxicity with camitine [Abstract]. Ann Neurol 1989;26:456.
  • 64
    Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatric 1981;99:3179.
  • 65
    Rawat S, Borkowski WJ Jr, Swick HM. Valproic acid and secondary hyperammonia. Neurology 1981; 31:11734.
  • 66
    Freeman JM, Vining EPG, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. Pediatrics 1994; 93:8935.
  • 67
    Coulter DL. Camitine and anticonvulsant drugs. In: PeruccaE, ed. L-Carnitine in the pharmacotherapy of epilepsy. Milan , Italy : Adis International, 1994:915.
  • 68
    Borum PR. Carnitine in neonatal nutrition. J Child Neurol 1995; 10(2):2S2531.
  • 69
    Vockley J. The changing face of disorders of fatty acid oxidation. Muyo Clin Proc 1994;69(3):24957.
  • 70
    Mak IT, Kramer JH, Weglicki WB. Potentiation of free radical-induced lipid peroxidative injury to sarcolemmal membranes by lipid amphiphiles. J Biol Chem 1986;26:11537.
  • 71
    Inoue D, Pappano AJ. L-Palmitoylcarnitine and calcium ions act similarly on excitatory ionic currents in avian ventricular muscle. Circ Res 1983;52:62534.
  • 72
    Spedding M. Activators and inactivators of Ca++ channels: new perspectives. J Pharmacol (Paris) 1985; 16:31943.
  • 73
    Spedding M, Mir AK. Direct activation of Ca2+ channels by palmitoyl camitine, a putative endogenous ligand. Br J Pharmacol 1987;92:45768.